COMPANY

Mustang Bio

HQ: Waltham, MA source · mustangbio.com ↗ · New England

Keywords: cell therapy oncology hematology solid tumor Follicular B-cell Non-Hodgkin's Lymphoma Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Relapsed Small Lymphocytic Lymphoma Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia Refractory B-cell Lymphoma Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Chronic Lymphoid Leukemia in Relapse Chronic Lymphocytic Leukemia in Relapse Hairy Cell Leukemia Diffuse Large B Cell Lymphoma MB-106 MB-102

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$8.0MRaised (2 yrs)3Trials (company is sponsor)2NIH grants

Timeline

Feb 10, 2025 Raise Follow-on offering: $8M (total, as published), announced Feb 10, 2025. Source: SEC filing. source ↗
May 24, 2022 Trial start Phase 1/Phase 2: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL source ↗
Sep 29, 2021 Trial start —: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. source ↗
Feb 17, 2020 Trial start Phase 1/Phase 2: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. source ↗

Funding

Raised: $8.0M. Last 2 years.

Feb 10, 2025 Follow-on offering: $8M (total, as published), announced Feb 10, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05360238	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	Phase 1/Phase 2	Terminated	May 24, 2022	Apr 12, 2024 (actual)
NCT04109482	Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.	Phase 1/Phase 2	Terminated	Feb 17, 2020	May 17, 2023 (actual)
NCT05645744	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	Not listed	Terminated	Sep 29, 2021	Apr 12, 2024 (actual)

NIH awards 2

Annual award amounts. Total $2.0M.

Aug 23, 2022 NIH award 5R44CA265616-02 FY2022: $999,336 awarded for that fiscal year; activity R44 (SBIR); PI LITCHMAN, MANUEL; recipient as written: MUSTANG BIO, INC., WORCESTER, MA. A Phase 1, Open Label, Multicenter Trial to A source ↗
Sep 16, 2021 NIH award 1R44CA265616-01 FY2021: $999,336 awarded for that fiscal year; activity R44 (SBIR); PI LITCHMAN, MANUEL; recipient as written: MUSTANG BIO, INC., WORCESTER, MA. A Phase 1, Open Label, Multicenter Trial to A source ↗